摘要
目的完善ICR小鼠背景数据。方法取48只正常青年ICR小鼠,动物饲养1周后实施安乐死术并进行大体解剖观察,收集心脏、肝脏、脾脏、肺、肾脏等40多个脏器固定于10%中性缓冲福尔马林液中,完成石蜡切片制作后进行HE染色及组织病理学观察。结果所有小鼠大体解剖未见任何异常。所有镜下组织病理学改变均考虑为该系小鼠自发性病理改变。仅1例小鼠肺脏可见灶性增生性改变。低倍镜下可见肺实质中存在似岛屿样、细胞排列紧密的实体型嗜酸性组织团块,与周围组织界限清晰,组织团块对周围肺泡组织存在轻微的挤压,周围组织未见病理改变。高倍镜下可见团块中的细胞分化良好,胞核蓝染呈圆形、卵圆形、梭形或不规则形,核仁不明显,核分裂象少见;胞质丰富呈嗜酸性粉染,可见微小空泡;细胞之间界限模糊,细胞呈腺样排列。将该例小鼠的肺部病灶诊断为支气管-肺泡型肺腺瘤。结论这是首次在5~6周龄青年ICR小鼠中对肺腺瘤的报道,该例自发性肺腺瘤将ICR小鼠肺肿瘤的最早发生点定位到了5~6周龄。
Objectives To enrich the background changes of ICR mice.Methods Forty eight healthy young ICR mice were euthanized and observed for gross anatomy after one week.More than 40 organs including heart,liver,spleen,lung and kidney were collected and fixed in 10%neutral buffered formalin solution.Paraffin sections were made for HE staining and histopathological observation.Results The gross anatomy of all mice was normal.All the histopathological changes were considered as spontaneous pathological changes.Only one mouse lung showed focal proliferative changes.Under the low power microscope,there were island like solid eosinophilic tissue masses with closely arranged cells in the lung parenchyma,with clear boundaries with the surrounding tissues.The tissue masses had slight compression on the surrounding alveolar tissues,and no pathological changes were found in the surrounding tissues.At high magnification,the cells in the mass were well differentiated with round,oval,fusiform or irregular nuclei stained with blue,unclear nucleoli and rare mitotic figures;the cytoplasm was abundant with eosinophilic powder staining and tiny vacuoles;the boundaries between cells were blurred and the cells were arranged in adenoid.The lung lesion of this mouse was diagnosed as bronchoalveolar pulmonary adenoma.Conclusion To the best of our knowledge,this is the first case report of the lung A/B adenoma in the young ICR mice and we reset the time of commence of the lung adenoma in ICR mice as young as 5~6 weeks old.
作者
周飞
倪家敏
黄暨生
ZHOU Fei;NI Jiamin;HUANG Jisheng(Drug Non-clinical Evaluation Center of Guangzhou Institute of Pharmaceutical Industry,Guangzhou General Pharmaceutical Research Institute,Guangzhou 510240,China)
出处
《药物评价研究》
CAS
2021年第4期711-714,共4页
Drug Evaluation Research
基金
国家科技重大专项重大新药创制(2018ZX09721004-001-003)。
